Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 17;9(1):30.
doi: 10.1186/s13048-016-0236-9.

Adoptive immunotherapy against ovarian cancer

Gloria Mittica  1   2 , Sonia Capellero  2 , Sofia Genta  1   2 , Celeste Cagnazzo  2 , Massimo Aglietta  1   2 , Dario Sangiolo  1   2 , Giorgio Valabrega  3   4   5
Affiliations
Review

Adoptive immunotherapy against ovarian cancer

Gloria Mittica et al. J Ovarian Res. .

Abstract

The standard front-line therapy for epithelial ovarian cancer (EOC) is combination of debulking surgery and platinum-based chemotherapy. Nevertheless, the majority of patients experience disease recurrence. Although extensive efforts to find new therapeutic options, cancer cells invariably develop drug resistance and disease progression. New therapeutic strategies are needed to improve prognosis of patients with advanced EOC.Recently, several preclinical and clinical studies investigated feasibility and activity of adoptive immunotherapy in EOC. Our aim is to highlight prospective of adoptive immunotherapy in EOC, focusing on HLA-restricted Tumor Infiltrating Lymphocytes (TILs), and MHC-independent immune effectors such as natural killer (NK), and cytokine-induced killer (CIK). Adoptive cell therapy (ACT) has shown activity in several pre-clinical models. Available preclinical and clinical data suggest that adoptive cell therapy may provide the best benefit in settings of low tumor burden, minimal residual disease, or maintenance therapy. Further studies are needed to better define the optimal clinical setting.

Keywords: Adoptive-cell therapy; CIK; LAK; NK; Ovarian Cancer; TILs.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of the main features and limits of TAA-specific and TAA-independent adoptive immunotherapy strategies against ovarian cancer. CAR: Chimeric-antigen receptors; CIK: Cytokine-induced killer; HLA: Human leukocyte antigen; LAK: Lymphokine Activated Killer; NK: Natural killer; TAA: Tumor associated antigen; TIL: Tumor-infiltrating lymphocytes
See this image and copyright information in PMC

References

    1. Wefers C, Lambert LJ, Torensma R, Hato SV. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence. Gynecol Oncol. 2015. - PubMed
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Hung CF, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008;222:43–69. doi: 10.1111/j.1600-065X.2008.00622.x. - DOI - PMC - PubMed
    1. Zsiros E, Tanyi J, Balint K, Kandalaft LE. Immunotherapy for ovarian cancer: recent advances and perspectives. Curr Opin Oncol. 2014;26:492–500. doi: 10.1097/CCO.0000000000000111. - DOI - PubMed
    1. Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–725. doi: 10.1038/nrc3144. - DOI - PMC - PubMed

MeSH terms